These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 18688246)

  • 1. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment.
    Wang J; Lozier J; Johnson G; Kirshner S; Verthelyi D; Pariser A; Shores E; Rosenberg A
    Nat Biotechnol; 2008 Aug; 26(8):901-8. PubMed ID: 18688246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction.
    Kishnani PS; Dickson PI; Muldowney L; Lee JJ; Rosenberg A; Abichandani R; Bluestone JA; Burton BK; Dewey M; Freitas A; Gavin D; Griebel D; Hogan M; Holland S; Tanpaiboon P; Turka LA; Utz JJ; Wang YM; Whitley CB; Kazi ZB; Pariser AR
    Mol Genet Metab; 2016 Feb; 117(2):66-83. PubMed ID: 26597321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders.
    Broomfield A; Jones SA; Hughes SM; Bigger BW
    J Inherit Metab Dis; 2016 Jul; 39(4):499-512. PubMed ID: 26883220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LSDs and the immune system.
    Beck M; Vanier M
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S85. PubMed ID: 20040317
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment prospects of lysosomal storage disorders].
    Reismann P; Tulassay Z
    Orv Hetil; 2008 Jun; 149(25):1171-9. PubMed ID: 18547894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximizing the therapeutic potential of enzyme replacement therapy for lysosomal storage diseases.
    Gieselmann V
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):707-8. PubMed ID: 19954707
    [No Abstract]   [Full Text] [Related]  

  • 7. Perspectives from B cell immunology: fact and fancy.
    Hunt SV
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S86-99. PubMed ID: 20040318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of lysosomal storage disease.
    Wraith JE
    Dev Med Child Neurol; 2001 Sep; 43(9):639-46. PubMed ID: 11570635
    [No Abstract]   [Full Text] [Related]  

  • 9. Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder.
    Brooks DA; Kakavanos R; Hopwood JJ
    Trends Mol Med; 2003 Oct; 9(10):450-3. PubMed ID: 14557058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on treatment of lysosomal storage diseases.
    Bruni S; Loschi L; Incerti C; Gabrielli O; Coppa GV
    Acta Myol; 2007 Jul; 26(1):87-92. PubMed ID: 17915580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement and enhancement therapies for lysosomal diseases.
    Desnick RJ
    J Inherit Metab Dis; 2004; 27(3):385-410. PubMed ID: 15190196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme enhancement therapeutics for lysosomal storage diseases: Current status and perspective.
    Thomas R; Kermode AR
    Mol Genet Metab; 2019 Feb; 126(2):83-97. PubMed ID: 30528228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in development of transgenic silkworms overexpressing recombinant human proteins with therapeutic potential in silk glands.
    Itoh K; Kobayashi I; Nishioka S; Sezutsu H; Machii H; Tamura T
    Drug Discov Ther; 2016 Feb; 10(1):34-9. PubMed ID: 26971553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glyco-engineering strategies for the development of therapeutic enzymes with improved efficacy for the treatment of lysosomal storage diseases.
    Oh DB
    BMB Rep; 2015 Aug; 48(8):438-44. PubMed ID: 25999178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson P; Peinovich M; McEntee M; Lester T; Le S; Krieger A; Manuel H; Jabagat C; Passage M; Kakkis ED
    J Clin Invest; 2008 Aug; 118(8):2868-76. PubMed ID: 18654665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzyme Replacement Therapy for Lysosomal Storage Diseases.
    Kleppin S
    J Infus Nurs; 2020; 43(5):243-245. PubMed ID: 32881810
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).
    Liao K; Sikkema D; Wang C; Lee TN
    J Immunol Methods; 2013 Mar; 389(1-2):52-60. PubMed ID: 23298658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity.
    Fan JQ
    Biol Chem; 2008 Jan; 389(1):1-11. PubMed ID: 18095864
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Enzyme replacement therapy for lysosomal storage disorders].
    Valayannopoulos V; Brassier A; Chabli A; Caillaud C; Lemoine M; Odent T; Arnoux JB; de Lonlay P
    Arch Pediatr; 2011 Oct; 18(10):1119-23. PubMed ID: 21873040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysosomal storage diseases: current therapies and future alternatives.
    Leal AF; Espejo-Mojica AJ; Sánchez OF; Ramírez CM; Reyes LH; Cruz JC; Alméciga-Díaz CJ
    J Mol Med (Berl); 2020 Jul; 98(7):931-946. PubMed ID: 32529345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.